FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA approves a supplemental application for Revlimid (lenalidomide) submitted by Celgene Corporation, updating regulatory status for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome with 5q Deletion
• Small Lymphocytic Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

SUPPL AP for REVLIMID (LENALIDOMIDE)